Infection risk and stability of a continuous 8-h 250 mL rFVIII infusion

Area of Science:

• Hematology
• Pharmacology
• Infectious Disease

Background:

• Hemophilia A treatment often involves Factor VIII (FVIII) replacement therapy.
• Continuous infusion methods aim for stable FVIII levels but may require specialized equipment.
• Assessing infection risk associated with prolonged infusions is crucial for patient safety.

Purpose of the Study:

• To evaluate the efficacy and safety of an 8-hour continuous infusion of Factor VIII (FVIII) using a standard 250 cc IV bag and pump.
• To determine the infection risk associated with this 8-hour continuous infusion method in hemophilia A patients.

Main Methods:

• Ten hemophilia A patients received a bolus FVIII infusion followed by an 8-hour continuous infusion of Kogenate FS (™).
• FVIII levels were measured in the IV bag and peripherally from patients at multiple time points.
• Blood cultures were drawn from the IV bag and tubing to assess for microbial contamination.

Main Results:

• FVIII levels in patients remained consistent with IV bag values throughout the 8-hour infusion (P-value range 0.36-0.9).
• All blood cultures, from both the IV bag and patients, were negative, indicating no infection.
• The study confirmed effective FVIII delivery and safety with the 8-hour continuous infusion method.

Conclusions:

• An 8-hour continuous infusion of FVIII using standard IV bags and pumps is an effective and safe delivery method.
• This method presents a viable alternative for FVIII administration, particularly in settings lacking specialized pumps.
• The study demonstrated no increased infection risk with this prolonged infusion protocol.